Market Access Strategic Consulting
We design integrated market access solutions that connect Clinical, Regulatory, Medical, Commercial and Market Access functions from early development through to launch.
Market Access & Funded PA-NPP Services
As specialists in Early Access Programs and the unlicensed medicine space, we help bridge the gap between clinical development and commercialization, supporting timely execution, strategic launch planning, and risk mitigation across the product lifecycle.
Strategic
Consulting
Integrated Evidence Strategy
At WEP, our commitment to exceptional service sets us apart. We are:
Agile in our strategic thinking
Subject Matter Experts
Experienced in tactical planning
Strategic Consulting
Global frameworks and structured planning help shape post-trial access through to launch strategies and coordinate cross-functional teams in implementation and execution. Landscape analysis and stakeholder research provide insight into local market conditions and payer expectations and priorities.
We support global and affiliate level teams to develop integrated Centres of Excellence and global access frameworks to guide strategic launch planning and cross-functional coordination.
We assess market access, regulatory, medical, and competitive environments to identify risks and opportunities specific to your asset. Insights are used to shape launch strategies that align with local payer expectations.
We conduct targeted research with a network of international payers and KOLs to inform value communication, evidence planning, and early and/or funded access feasibility.
Integrated Evidence Strategy
We conduct comprehensive reviews of clinical evidence and Real World Data (RWD) to support payer, HTA, and regulatory requirements. This ensures alignment with market expectations for access and reimbursement.
We conduct comprehensive reviews of clinical evidence and Real World Data (RWD) to support payer, HTA, and regulatory requirements. This ensures alignment with market expectations for access and reimbursement.
We identify evidence gaps from a payer perspective, focusing on unmet needs in clinical outcomes, quality of life, and economic impact. This includes aligning evidence generation with the value drivers required by specific payer archetypes for access and reimbursement.
We work directly with KOLs, payers, and patient advocacy groups to design bespoke RWE plans to complement the evidence package of your asset. This can be inclusive of natural history data or other relevant RWD for that asset/portfolio.
Pricing &
Reimbursement Strategy
Pricing & Reimbursement strategies are developed using insights from payer research, value proposition testing, and scenario modelling across single and multiple indications. HTA and Market Access support is provided as part of market entry planning.
We collate payer insights through targeted market research and Payer Advisory Boards. These engagements help shape evidence generation priorities, inform access strategies, and refine value communications.
We test and refine value propositions using payer feedback to ensure alignment with decision-maker priorities across global healthcare systems.
We develop pricing strategies and scenario models across single and multiple indications considering the whole portfolio and development pipeline. This helps define price potential and optimize launch sequencing aligned to the overarching business strategy.
Funded Early Access (PA-NPP)
Funded named patient programs provide early access to treatment in key markets before local approval. These programs offer an opportunity for physician and patient experience in the real world setting and, in some markets, the option to gather real-world data to support sustainable access and value planning, and build advocacy among clinical and patient networks.
We facilitate early access through funded named patient programs which allow patients with unmet medical need to benefit from treatments prior to formal market entry.
Our team provides operational and regulatory support to enable early physician-led access in key countries. This includes identifying eligible markets and managing local stakeholder engagement.
We specialize in executing funded early access programs across Europe and globally. We engage with our established network of local regulatory experts to ensure compliant and efficient program delivery.
These programs offer a structured opportunity to collect real-world data and clinical experience as part of a broader evidence strategy. Data collected through these programs can help to support sustainable value demonstration and market access planning.
SUPPORTING A MEDICINE THROUGHOUT THE DEVELOPMENT JOURNEY
Condition: Rare autoimmune disease Approved in: US and Europe